HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Xeroderma pigmentosum variant: response to etretinate.

Abstract
We report a case of the variant form of xeroderma pigmentosum in whom tumour development was completely suppressed for 22 months by etretinate 25 mg daily.
AuthorsJ Berth-Jones, R A Graham-Brown
JournalThe British journal of dermatology (Br J Dermatol) Vol. 122 Issue 4 Pg. 559-61 (Apr 1990) ISSN: 0007-0963 [Print] England
PMID2337522 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Etretinate
Topics
  • DNA Repair (physiology)
  • Etretinate (administration & dosage, therapeutic use)
  • Humans
  • Male
  • Middle Aged
  • Skin Neoplasms (drug therapy, genetics)
  • Xeroderma Pigmentosum (drug therapy, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: